Skip to main content
Premium Trial:

Request an Annual Quote

ExonHit Licenses Array-Based Toxicity Ranking System to Mitsubishi Pharma

NEW YORK, Sept. 15 (GenomeWeb News) - ExonHit Therapeutics has licensed its microarray-based toxicity evaluation system, Safe-Hit, to Mitsubishi Pharma, the Paris-based company said today.


Safe-Hit allows users to evaluate and rank compounds according to their toxicity. The content of the microarray is based on a library of RNA splicing events specific to toxicity that ExonHit developed using a model of cellular stress. Mitsubishi evaluated the system for one year using its own compounds.

The Scan

Highly Similar

Researchers have uncovered bat viruses that are highly similar to SARS-CoV-2, according to Nature News.

Gain of Oversight

According to the Wall Street Journal, the Biden Administration is considering greater oversight of gain-of-function research.

Lasker for mRNA Vaccine Work

The Scientist reports that researchers whose work enabled the development of mRNA-based vaccines are among this year's Lasker Award winners

PLOS Papers on Causal Variant Mapping, Ancient Salmonella, ALK Fusion Test for NSCLC

In PLOS this week: MsCAVIAR approach to map causal variants, analysis of ancient Salmonella, and more.